文章：

复发性胶质母细胞瘤免疫治疗的发展

The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma

原文发布日期：29 August 2023

DOI: 10.3390/cancers15174308

类型: Article

开放获取: 是

英文摘要：

Recurrent glioblastoma (rGBM) is a highly aggressive form of brain cancer that poses a significant challenge for treatment in neuro-oncology, and the survival status of patients after relapse usually means rapid deterioration, thus becoming the leading cause of death among patients. In recent years, immunotherapy has emerged as a promising strategy for the treatment of recurrent glioblastoma by stimulating the body’s immune system to recognize and attack cancer cells, which could be used in combination with other treatments such as surgery, radiation, and chemotherapy to improve outcomes for patients with recurrent glioblastoma. This therapy combines several key methods such as the use of monoclonal antibodies, chimeric antigen receptor T cell (CAR-T) therapy, checkpoint inhibitors, oncolytic viral therapy cancer vaccines, and combination strategies. In this review, we mainly document the latest immunotherapies for the treatment of glioblastoma and especially focus on rGBM.

摘要翻译： 

复发性胶质母细胞瘤（rGBM）是一种高度侵袭性的脑癌，对神经肿瘤学的治疗构成重大挑战，患者复发后的生存状态通常意味着迅速恶化，因此成为患者死亡的主要原因。近年来，免疫疗法已成为治疗复发性胶质母细胞瘤的一种有前景的策略，通过刺激机体免疫系统识别并攻击癌细胞，可与手术、放疗和化疗等其他治疗方法联合使用，以改善复发性胶质母细胞瘤患者的预后。该疗法结合了多种关键方法，包括单克隆抗体、嵌合抗原受体T细胞（CAR-T）疗法、检查点抑制剂、溶瘤病毒疗法、癌症疫苗以及联合策略。本文主要综述了治疗胶质母细胞瘤尤其是rGBM的最新免疫疗法。

原文链接：

The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma